Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1197720170100030123
´ëÇÑÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸÁö
2017 Volume.10 No. 3 p.123 ~ p.129
Sleepiness and Depression in Parkinson¡¯s Disease Patients Treated with Ropinirole and Levodopa
Kang Suk-Yun

Ryu Ho-Sung
Sunwoo Mun-Kyung
Kim Sang-Jin
Baik Jong-Sam
Park Mee-Young
Park Hyung-Eun
Kim Joong-Seok
Kwon Kyum-Yil
Koh Seong-Beom
Kim Young-Eun
Lee Mi-Kyong
Chung Sun-Ju
Sohn Young-Ho
Abstract
Objective: We aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson¡¯s disease (PD) with a large population.

Methods: We conducted a cross-sectional observational study at nine hospitals in Korea between April 24, 2013, and April 22, 2015. We analyzed the demographic and clinical features, other medical history, history of antiparkinsonian medication within 6 months, Hoehn and Yahr stage (HY stage), Unified Parkinson¡¯s Disease Rating Scale (UPDRS) part II and III, Epworth Sleepiness Scale (ESS), and 30-item Geriatric Depression Scale (GDS-30).

Results: Four-hundred-thirteen patients with PD (mean age: 65.2 ¡¾ 9.0 years; men: 227 patients) were analyzed. Multivariate logistic regression analysis showed that age at examination, UPDRS II, and GDS-30 were independent risk factors for EDS and that sex, UPDRS II, and ESS were independent risk factors for depression.

Conclusion: Our large group study did not find any significant associations of ropinirole with EDS and depression in Korean PD patients.
KEYWORD
Parkinson¡¯s disease, ropinirole, levodopa, sleepiness, mood, excessive daytime sleepiness, depression
FullTexts / Linksout information
 
Listed journal information